Log in

NASDAQ:NPSP - Shire-Nps Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NPS Pharmaceuticals, Inc (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:NPSP
CUSIP62936P10
Phone+1-908-4505300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NPSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NPSP and its competitors with MarketBeat's FREE daily newsletter.


Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions

What is Shire-Nps Pharmaceuticals' stock symbol?

Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were Shire-Nps Pharmaceuticals' earnings last quarter?

Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) issued its quarterly earnings data on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to analyst estimates of $69.30 million. View Shire-Nps Pharmaceuticals' Earnings History.

Has Shire-Nps Pharmaceuticals been receiving favorable news coverage?

Media headlines about NPSP stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Shire-Nps Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Shire-Nps Pharmaceuticals.

Who are some of Shire-Nps Pharmaceuticals' key competitors?

What other stocks do shareholders of Shire-Nps Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire-Nps Pharmaceuticals investors own include Gilead Sciences (gild), Intercept Pharmaceuticals (ICPT), Celgene (CELG), Pharmacyclics (PCYC), General Electric (GE), GW Pharmaceuticals PLC- (GWPH), Pfizer (PFE), FireEye (FEYE), Starbucks (SBUX) and ACADIA Pharmaceuticals (ACAD).

What is Shire-Nps Pharmaceuticals' official website?

The official website for Shire-Nps Pharmaceuticals is http://www.npsp.com/.

How can I contact Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.


MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NASDAQ NPSP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe NPSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NPSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Profit Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel